

Texas Department of State Health Services

Hepatitis C Surveillance in Texas

Carlos R. Alvarez, MPH, CPH ELC Conference 2019 Austin, TX





Texas Department of State Health Services

- Overview of HCV
- Hepatitis C in the United States
- Hepatitis C in Texas
- HCV surveillance
- CSTE Case definition
- HCV surveillance data
- Questions


10/21/2019

Hepatitis C Overview



Texas Department of State Health Services


- Blood-Borne Virus
- Previously known as non-A, non-B hepatitis
- Incubation time of 14 to 180 days
 - Average 2-12 weeks
- Causes inflammation of the liver leading to cirrhosis, liver failure and hepatocellular carcinoma (HCC)



Hepatitis C Transmission



Texas Department of State Health Services






Clinical Symptoms

Texas Department of State Health Services

- Fever
- Fatigue
- Dark urine
- Clay-colored stool
- Abdominal pain



- Loss of appetite
- Nausea
- Vomiting
- Joint pain
- Jaundice

70%-80% of people infected do not experience any symptoms
These clinical symptoms are considered clinical criteria for surveillance purposes

Risk factors

- 1. Born Between 1945 and 1965
- 2. HIV Positive
- 3. History of sexually transmitted diseases
- 4. Men who have sex with men (MSM)
- 5. Injection drug use (IDU)
- 6. Intranasal drug use (INDU)
- 7. Had sex for money/drugs
- 8. Prior/current incarceration
- 9. Employed in medical/dental field
- 10. Child born to hepatitis C + mother\
- 11. Received clotting factors, blood/blood products or organ transplant before 1992
- 12. Household Contact of confirmed or suspect to HCV case
- 13. Long term hemodialysis




Texas Department of State Health Services

Hepatitis C in the United States

- Most common blood-borne infection in the US
- An estimated 2.3 million persons in the United States are living with hepatitis C²
- In 2013, HCV killed more people than all other infectious diseases reported to CDC³
- 25% of those living with HIV in the US are co-infected with hepatitis C virus (HCV)¹



Health Services





 In 2015, Estimated 584,196 (357,098 to 1,313,077) people in Texas living with Chronic Hepatitis C

Based on the U.S. Census 2015 Texas population estimated at 27,469,114 and a national published hepatitis C prevalence rate estimate from 2003-2010 NHANES data (adjusted for the limitations of not including populations of homeless, incarcerated, and institutionalized persons) of 1.3 percent

Hepatitis C Surveillance Team currently working on updating prevalence estimate

NEDSS

Mortality Data

Hospitalizations

Other



Health Services

HCV Surveillance in Texas

- Historically, HCV surveillance activities were housed in EAIDB
- April 2017, TB/HIV/STD Branch begin discussion regarding the transfer of surveillance responsibilities from EAIDB to TB/HIV/STD
- October 2017, 3 HCV epidemiologist and one clinical data specialist join staff in TB/HIV/STD Branch as the HCV Surveillance Team
- November 2017, Official HCV surveillance transfer date from EAIDB to HIV/STD/TB




Health Services

Surveillance Flow



Texas Department of State Health Services







Texas Department of State Health Services

- Laboratories
 - ELRs
 - Paper Labs
- Providers
 - Infectious Disease Report for Notifiable Diseases

10/21/2019

CSTE Acute Case Definition



Texas Department of State
Health Services

Clinical Case Definition

 Acute: An acute illness with discrete onset of symptoms* consistent with acute viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain), and a) jaundice or b) abnormal serum alanine aminotransferase levels (ALT level >200 IU/L).

*A documented negative HCV laboratory test result of any type (antibody, antigen, NAT/PCR) followed within 12 months by a positive test result of any type does not require an acute clinical presentation to meet the surveillance case definition.

Laboratory Confirmation

- Nucleic acid test (NAT) or PCR test for HCV RNA positive (including qualitative, quantitative or genotype testing) OR
- A positive test indicating presence of hepatitis C viral antigen (HCV antigen)*
- * When and if a test for HCV antigen(s) is approved by FDA and available

CSTE Acute Case Classification



Health Services

Case Classification


Confirmed:

- A case that meets clinical criteria and is laboratory confirmed OR
- A documented negative HCV test result (antibody/anti-HCV, antigen, or NAT/PCR) followed within 12 months by a positive result of any of these tests (test conversion – does not require acute clinical presentation).


Probable:

A case that meets clinical criteria and has a positive anti-HCV antibody test, but has no reports of a positive HCV NAT or positive HCV antigen tests, AND does not have evidence of test conversion within 12 months or has no report of test conversion.













































Acute Hepatitis C Cases by Race in Texas, 2018 Acute Hepatitis C Cases by Sex in Texas, 2018 (N=76)


■ Black or AA, NH

Hispanic

White, NHUnknown

Other








Texas Department of State Health Services

Acute Hepatitis C Cases by Age in Texas, 2018 (N=76)





Current Projects

- Epi Profile
- HIV/HCV Data Match
- HCV Surveillance Training
- HCV Provider Tool
- Vulnerability Assessment
- TACKLE HIV/HCV
- HCV Testing Sites



Texas Department of State Health Services

Questions?



Texas Department of State Health Services





Texas Department of State Health Services

Acknowledgements

- Vittoria Criss, HCV Prevention Coordinator
- Ashley Margo, Clinical Data Specialist
- Shelley Lucas, HIV/STD Prevention and Care Branch Manager

Contact:

Carlos R. Alvarez

carlos.alvarez@dshs.texas.gov

512-533-3125

10/21/2019